Redx Pharma (GB:REDX) has released an update.
Redx Pharma has announced the successful passing of all resolutions at the General Meeting, including the cancellation of its listing on the AIM market, with the delisting to take effect on May 1, 2024. In light of the delisting, Redx plans to set up a matched bargain facility to assist shareholders in trading their shares. The biotech firm, known for developing small molecule therapeutics for cancer and fibrotic diseases, continues to progress with its clinical trials, including its lead fibrosis product, zelasudil, and its oncology candidate, zamaporvint.
For further insights into GB:REDX stock, check out TipRanks’ Stock Analysis page.
